A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of diseas

Publication Type:

Journal Article


Journal of translational medicine, Volume 6, p.6 (2008)


2008, Adolescent, Adult, APOPTOSIS, Cancer Vaccines, Center-Authored Paper, Clinical Research Division, Cytokine Analysis Core Facility, DENDRITIC CELLS, DISEASE PROGRESSION, Female, Flow Cytometry Core Facility, Genotype, Humans, Hypersensitivity, Delayed, Immune Monitoring Core Facility, Interleukin-10, Lymphocyte Activation, Male, MELANOMA, Middle Aged, Necrosis, Neoplasm Staging, Patient Selection, Phagocytosis, Polymorphism, Genetic, Predictive Value of Tests, Promoter Regions, Genetic, Shared Resources, Transplantation, Autologous


Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in a Phase I study with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs) loaded with a mixture of apoptotic/necrotic allogeneic melanoma cell lines (Apo-Nec), to evaluate toxicity and immune responses. Also, IL-10 1082 genotype was analyzed in an effort to predict disease progression.